Pfizer and Innovent Biologics have formed a global oncology partnership valued at up to $10.5 billion. This collaboration highlights the increasing interest from multinational pharmaceutical companies in innovative therapies developed by Chinese biotech firms. Following the announcement, Innovent Biologics' shares listed in Hong Kong saw a significant jump of over 11%.

Deere & Company (NYSE:DE) has received a "Moderate Buy" consensus recommendation from 24 brokerages, with an average 12-month price target of $638.08. The company reported strong Q1 earnings, with EPS of $6.55 and revenue of $13.37 billion, both surpassing expectations, and declared a quarterly dividend of $1.62 per share. Analyst sentiment is mixed, balancing positive demand in construction and small agriculture with concerns over margin pressure and softer agricultural conditions.

Mallorie Burak, the CEO & CFO of Energous Corp (WATT), recently purchased 1,867 shares, increasing her total ownership to 26,999 shares. This transaction follows a pattern of insider buying within the last year, with 2 insider buys and no sells. Energous stock was trading at $26.47, considered fairly valued against its GF Value of $30.35.

Wipro's shares surged after the company announced an expanded partnership with ServiceNow to integrate Wipro Intelligence with the ServiceNow AI Platform. This collaboration aims to scale agentic AI workflows across various enterprise functions, including IT, HR, procurement, and cybersecurity. The deal led to Wipro's American Depositary Receipts (ADRs) surging by 18.5%, indicating a potential significant rally for its Indian shares.

Wipro Ltd. (NYSE:WIT) experienced an 18.54% stock price jump after announcing an aggressive plan to buy back $1.8 billion worth of its shares. This repurchase program, involving 5.7% of outstanding shares at a premium, aims to boost stock price, signal confidence in growth, and enhance shareholder value. Investors holding American depositary shares must convert them to direct shares to participate.

US Foods Holding Corp (USFD) is drawing investor attention as it prepares to present at the Deutsche Bank Access Global Consumer Conference 2026. Investors are keen for updates on the company's strategy, margins, and capital allocation, especially since no new earnings or guidance updates have been issued recently. The company's performance, given its competitive foodservice landscape, will be closely watched for commentary on customer trends and volume patterns.

Akari Therapeutics announced the acceptance of its first abstract at the 2026 ASCO Annual Meeting, a significant validation for the company's differentiated ADC platform. President and CEO Abizer Gaslightwala highlighted preclinical data targeting difficult-to-treat cancers like KRAS-driven tumors. The company believes its AKTX-101 and novel spliceosome-modulating payload approach can revolutionize KRAS-driven cancer treatment.

Four major insurance organizations, The Hartford, Unum Group, Alliant Insurance Services, and Core Specialty, have announced significant leadership and board changes this week. These moves include new appointments in ocean marine underwriting, group insurance governance, transactional risk broking, and changes to board composition, reflecting strategic adjustments in the insurance industry. The changes emphasize succession planning, growth in M&A insurance, and disciplined specialty underwriting.

Nordson Corp's fiscal Q2 2026 earnings exceeded expectations, supported by a higher price target of USD 345 from DA Davidson. The stock continues to be a focus for investors on Nasdaq, trading around USD 288 per share with continued institutional interest. The company's strong performance and "Moderate Buy" consensus reinforce its position in industrial automation markets.

Morgan Stanley has raised its price target for Carrier Global Corp. (CARR) to $60 from $55, maintaining an "Equal Weight" rating, despite shares trading slightly lower on the NYSE on May 28, 2026. This adjustment comes as the HVAC specialist's stock has seen recent consolidation after a strong run, and the new target is modestly below recent trading levels but consistent with a neutral stance. The broader analyst consensus, however, shows an average target price of approximately $76.31, suggesting a higher valuation than implied by Morgan Stanley's latest assessment.